Back to results
US 2020/0392230 A1Published application
Bispecific anti-cd3 x cd20 antibodies and uses thereof
AssigneeQLB Biotherapeutics
InventorsChao TU, Rijian WANG
Life of this patent
Estimating the term…
Abstract
The disclosure relates to bispecific anti-CD3×CD20 antibodies comprising (i) a single-chain CD3 binding moiety, (ii) a single-chain CD20 binding moiety, and preferably (iii) an Fc region. Aspects of the disclosure further relate to compositions comprising these bispecific antibodies, vectors comprising one or more polynucleotides encoding these bispecific antibodies, as well as uses of these bispecific antibodies for treating a subject suffering from a B cell-related cancer, in particular, a subject who has developed resistance to anti-CD20, e.g., rituximab, therapy.
Claims26
A bispecific antibody comprising:
- (i) a single-chain CD3 binding moiety comprising a heavy chain variable domain (VH) operably linked to a light chain variable domain (VL) via a first peptide linker, wherein
- the VH comprises a heavy chain CDR1 comprising SEQ ID NO:
- 1, a heavy chain CDR2 comprising SEQ ID NO:
- 2, and a heavy chain CDR3 comprising SEQ ID NO:
- 3;
- and
- the VL comprises a light chain CDR1 comprising SEQ ID NO:
- 4, a light chain CDR2 comprising SEQ ID NO:
- 5, and a light chain CDR3 comprising SEQ ID NO:
- 6, and
- (ii) a single-chain CD20 binding moiety comprising a VH operably linked to a VL via a second peptide linker, wherein
- the VH comprises a heavy chain CDR1 comprising SEQ ID NO:
- 7, a heavy chain CDR2 comprising SEQ ID NO:
- 8, and a heavy chain CDR3 comprising SEQ ID NO:
- 9;
- and
- the VL comprises a light chain CDR1 comprising SEQ ID NO:
- 10, a light chain CDR2 comprising SEQ ID NO:
- 11, and a light chain CDR3 comprising SEQ ID NO:
- 12.
17 more elements
Dependencies are inferred from the claim text.